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Although Zika virus (ZIKV) can be transmitted sexually and cause congenital birth defects,
immune control mechanisms in the female reproductive tract (FRT) are not well character-
ized. Here we show that treatment of primary human vaginal and cervical epithelial cells
with interferon (IFN)-α/β or IFN-λ induces host defense transcriptional signatures and
inhibits ZIKV infection. We also assess the effects of IFNs on intravaginal infection of the FRT
using ovariectomized mice treated with reproductive hormones. We ﬁnd that mice receiving
estradiol are protected against intravaginal ZIKV infection, independently of IFN-α/β or IFN-λ
signaling. In contrast, mice lacking IFN-λ signaling sustain greater FRT infection when pro-
gesterone is administered. Exogenous IFN-λ treatment confers an antiviral effect when mice
receive both estradiol and progesterone, but not progesterone alone. Our results identify a
hormonal stage-dependent role for IFN-λ in controlling ZIKV infection in the FRT and suggest
a path for minimizing sexual transmission of ZIKV in women.
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Zika virus (ZIKV) is an emerging mosquito-transmittedﬂavivirus that can cause congenital birth defects duringinfection of pregnant women, non-human primates
(NHP), and mice1–7. Unlike other ﬂaviviruses, ZIKV can be
transmitted sexually in addition to by mosquito inoculation8–11.
Recent studies suggest that sexual transmission of ZIKV may be
underestimated12, and its consequences to the female reproduc-
tive tract (FRT) have not been extensively evaluated. In com-
parison, ZIKV infection can persist in the testes, seminal ﬂuid,
and sperm, which is associated with oligospermia in humans2,13
and testicular atrophy and decreased fertility in mice1,2,14–16. Less
is known about which cell types ZIKV targets in the FRT,
although studies in mice and NHPs indicate that sexual exposure
leads to productive infection of the vagina8,17–20
In women, the vaginal epithelium is the ﬁrst line of defense
against sexually transmitted diseases. The menstrual cycle is
regulated hormonally to optimize conditions for ovulation,
implantation, and conception. As part of this process, the thick-
ness and components of the epithelial barrier in the vagina vary
through stages of the estrous cycle in mice and menstrual cycle in
humans21,22. In mice, this results in resistance to intravaginal
infection with ZIKV or herpes simplex virus (HSV) during the
estradiol-high, estrous phase but susceptibility during the pro-
gesterone-high, diestrous phase18,23,24. The mechanistic basis for
these hormonal stage-dependent changes in susceptibility to
infection remains largely unknown.
The innate immune response acts as a barrier against sexually
transmitted diseases. One study reported that interferon (IFN)-ε,
a type I IFN subtype that signals through Ifnar1/Ifnar2 hetero-
dimers25, is constitutively expressed by epithelial cells in the
uterus, cervix, vagina, and ovary and protects the FRT of mice
from intravaginal infection with HSV26. However, the role of
IFN-ε in other viral infections, or in humans, remains uncertain.
For example, ZIKV replicates in the vaginal mucosa of mice with
minimal induction of antiviral type I IFN responses27. This latter
study also reported that intravaginal treatment with acitretin, a
highly teratogenic retinoic acid derivative28, induced type I (α/β)
and III (λ) IFNs and resulted in diminished ZIKV infection. Type
III IFN-λ is an antiviral cytokine that functions at barrier surfaces
and is induced downstream of pathogen recognition receptor
sensing and activation of mitochondrial antiviral signaling pro-
tein (MAVS)29. IFN-λ binds to and signals through selectively
expressed heterodimeric receptors (Ifnlr1/Il10rβ), which distin-
guishes it from type I IFNs that bind to the more broadly
expressed Ifnar1/Ifnar2 heterodimers. IFN-λ has antiviral func-
tions against ZIKV in the context of infection of the maternally
derived decidua and fetally derived placenta during pregnancy in
mice and humans30–32.
Here, we evaluate ZIKV infection and host responses in the
tissues of the FRT. Initial experiments in primary human vaginal
and cervical epithelial cells demonstrate that IFN-β or IFN-λ
treatment induces transcriptional programs that inhibit ZIKV
infection. By performing studies in hormone-synchronized, non-
pregnant, ovariectomized (OVX) female mice, we conﬁrm resis-
tance to intravaginal ZIKV infection during the estradiol-high,
estrous phase and susceptibility during the progesterone-high,
diestrous phase17,18. As mice lacking type I IFN signaling
responses are resistant to intravaginal ZIKV infection during the
estrous phase, IFN-ε likely is not the dominant contributing
factor to protection during the estrous phase of the reproductive
cycle. As ZIKV replicates to higher levels in the vaginal and
cervical epithelial layers of progesterone-treated Ifnlr1−/− than
wild-type (WT) mice, these data suggest that IFN-λ signaling
contributes to the antiviral response in the FRT in the diestrous
phase. However, Ifnlr1−/−and WT mice sustain similar levels of
ZIKV infection in FRT tissues when animals were treated with
estradiol and progesterone (proestrous phase, which corresponds
with the hormone proﬁle in the luteal phase of humans), sug-
gesting a hormonal stage-dependent effect of IFN-λ. Consistent
with the observation, IFN-λ is not induced after ZIKV infection
in mice treated with estradiol and progesterone. Nonetheless,
when pegylated IFN-λ2 is administered to mice treated with
estradiol and progesterone, markedly diminished ZIKV infection
is observed in the vagina, cervix, uterus, and other distant sites.
Collectively, these results provide insights into the tissue tropism
of ZIKV in the FRT, the effects of sex hormones on ZIKV
infectivity, and the innate immune response to ZIKV in the
vagina.
Results
Effects of IFN-β and -λ on human vaginal and cervical cells. To
begin to characterize the innate immune response of FRT tissues
to ZIKV infection, we ﬁrst evaluated the effect of recombinant
IFN-β and IFN-λ on ZIKV infection of primary human vaginal
epithelial cells (HVECs) obtained from four different donors and
primary human cervical epithelial cells (HCECs) obtained from
three donors. Pre-treatment of HVECs or HCECs with 100 ng of
IFN-β or IFN-λ1 reduced ZIKV infection by 32 to 39-fold
(HVECs) (P < 0.05) or 695 to 1575-fold (HCECs) (P < 0.01)
compared to mock-treated controls (Fig. 1a, b). To gain further
insight into the antiviral effects of IFN treatment on HVECs, we
performed whole-genome RNAseq-based transcriptional proﬁl-
ing of mock-, IFN-β-, or IFN-λ1-treated cells from three donors
followed by differential gene expression and gene set enrichment
analyses. IFN-λ1 treatment resulted in differential expression of
251 transcripts compared to 168 after IFN-β treatment (Supple-
mentary Figure 1a, b). Of these differentially expressed tran-
scripts, 162 were shared by IFN-β and IFN-λ1, 89 were induced
uniquely by IFN-λ1, and six were induced speciﬁcally by IFN-β
(Fig. 1c–f). Reverse transcriptase, quantitative polymerase chain
reaction (RT-qPCR) studies conﬁrmed the induction of a number
of canonical IFN-stimulated genes (ISGs) in HVECs and HCECs
treated with IFN-β or IFN-λ1 (Fig. 1g, h). Gene set enrichment
and differential expression analyses of transcripts speciﬁcally
modulated by IFN-λ1 treatment did not reveal any unique
pathways, but demonstrated that several ISGs (e.g., IFIT2, IRF1,
and IFI30) were induced more robustly by IFN-λ1 than IFN-β
(Fig. 1f and Supplementary Figure 1c–e). Taken together, type I
and type III IFNs induced a strong ISG response in human
FRT cells that resulted in reduced ZIKV infection.
ZIKV resistance during estrous phase is IFN-independent. Our
transcriptional data suggested that type I or III IFNs might confer
antiviral effects in the lower FRT. Since previous studies had
shown resistance to ZIKV and HSV infection during the estra-
diol-high, estrous phase18,33, we hypothesized that this might be
due in part to constitutive or rapidly induced expression of
antiviral IFNs. Indeed, prior data suggested that IFN-ε is
expressed in the vagina during the estradiol-high, estrous phase
and protected mice from HSV infection during the diestrous
phase26. We assessed the contribution of type I IFN signaling to
the antiviral effect of estradiol against intravaginal ZIKV infection
using Ifnar1−/− mice. However, estradiol-treated OVX Ifnar1−/−
mice remained resistant to intravaginal ZIKV infection. Tissue
samples from the vagina, cervix, uterus, serum, brain, and spleen
at 7 days post infection (dpi) had little ZIKV RNA (Fig. 2a–f). In
comparison, vehicle or progesterone treatment of OVX Ifnar1−/−
mice resulted in ZIKV infection of all ﬂuids and tissues tested. In
situ hybridization (ISH) with a ZIKV-speciﬁc RNA probe in
vaginal tissues from Ifnar1−/− mice treated with vehicle or pro-
gesterone revealed infection of the epithelial layer and lamina
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propria, whereas animals treated with estradiol had virtually no
infection present (Fig. 2g, left panels). No marked tissue injury
was apparent in the vagina at 7 dpi, although a cellular inﬁltrate
was present in progesterone-treated, infected animals (Fig. 2g,
right panel).
To assess the effects of IFN-λ signaling on inhibition of ZIKV
infection in the FRT during the estradiol phase, we compared
intravaginal infection in OVX WT and Ifnlr1−/− mice with or
without estradiol treatment. We added a blocking anti-Ifnar1
monoclonal antibody (mAb) to OVX, hormone treated, WT, and
Ifnlr1−/− mice6,34 as ZIKV fails to antagonize type I IFN
signaling in murine cells35,36; indeed, in the absence of anti-Ifnar1
mAb treatment, little infection was observed at 7 dpi in WT or
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Fig. 1 IFN-λ restricts ZIKV infection of primary human vaginal and cervical epithelial cells. ZIKV infection titers from four preparations of primary human
vaginal epithelial cells (HVECs, a) and three preparations of primary human cervical epithelial cells (HCECs, b) treated with medium (mock) or 100 ng/mL
of IFN-β or IFN-λ1 (~16 h) and then infected with ZIKV (Paraiba 2015) for 48 h. Note, one of the biological preparations of HVECs was interrogated in two
separate experiments. Solid lines indicate mean values, and dotted lines denote limit of detection. c Venn diagram of transcripts differentially expressed by
IFN-β or IFN-λ1 treatment of HVEC as assessed by RNAseq. d, e Volcano plots of HVEC treated with IFN-β (d) or IFN-λ1 (e) denoting ISGs (red circles)
differentially expressed by treatment (P < 0.001, as determined using the DeSeq2 package in R). Transcripts that were not differentially expressed are
denoted by gray circles. f Hierarchical clustering heat map (based on log(RPKM) values) of the top 50 ISGs induced by treatment of HVECs with IFN-β or
IFN-λ1 compared to mock-treated controls. Color intensity indicates the level of gene expression (yellow for upregulation and blue for downregulation), and
gray indicates that no reads were detected for that transcript. g, h Induction of representative ISGs (IFI44L, OASL, OAS1, and MX1) after treatment of
HVECs (g) or HCECs (h) with 100 ng/mL of IFN-β or IFN-λ1 for 16 h as assessed by RT-qPCR. Statistical analyses in a, b, g, and h were performed using a
one-way ANOVA (ns= not signiﬁcant; *, P < 0.05 **, P < 0.01 ***, P < 0.001 ****, P < 0.0001)
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animals (estrous stage), which showed a thickened epithelial layer
(Supplementary Figure 3), were resistant to intravaginal ZIKV
infection in anti-Ifnar1 mAb-treated Ifnlr1−/− and WT mice
(Fig. 3a, c, d). In comparison, mice treated with vehicle,
progesterone only (diestrous stage), or estradiol and progesterone
(proestrous stage) were infected productively by ZIKV, with RNA
levels in all tested ﬂuids and tissues at 7 dpi. To conﬁrm the
functional effects of each hormone treatment, we performed
whole-genome RNA sequencing analysis on uninfected, OVX,
hormone-treated WT mice. Each hormone treatment produced a
unique transcriptional proﬁle (Supplementary Figure 4a) with
induction of expected, canonical hormone-regulated genes
(progesterone: Gpx3, Tcf23, Angptl7, Ctla2a, and Errﬁ1; estradiol:
Krt6b, Epn3, Ablim3, Greb1, and Rps2) (Supplementary Fig-
ure 4b). These data suggest that type I and type III IFNs do not
contribute substantively to the protective effect of estradiol
against intravaginal ZIKV infection.
IFN-λ protection of the vagina is hormone stage-dependent.
Although the vagina is a candidate epithelial barrier site for IFN-λ
responses29, a recent study showed minimal induction of IFN-α,
IFN-β, or IFN-λ during ZIKV or lymphocytic choriomeningitis
virus (LCMV) infection27. To further evaluate the signiﬁcance of
the IFN-λ response to infection within the FRT, we compared
intravaginal infection in WT and Ifnlr1−/− mice under hormone
conditions that are permissive for ZIKV replication. We again
added a blocking anti-Ifnar1 mAb to OVX WT and Ifnlr1−/−
mice to facilitate infection. Notably, progesterone only-treated
OVX Ifnlr1−/− mice sustained increased ZIKV infection in
vaginal lavage ﬂuid (147-fold, P < 0.01) at 3 dpi and in vaginal
tissues at 7 dpi (3.3-fold, P < 0.01) compared to similarly treated
OVX WT mice (Fig. 3a, b). In comparison, the cervix, uterus,
serum, brain, and spleen of progesterone only-treated OVX WT
and Ifnlr1−/− mice had similar levels of viral RNA (Fig. 3c, d
Supplementary Figure 5a–c). ZIKV appeared concentrated in the
epithelial layer of the vagina in progesterone only-treated mice
(Fig. 4a, top left), with Ifnlr1−/− mice showing increased intensity
of staining (Fig. 4a, bottom left). In comparison, vehicle-treated
OVX Ifnlr1−/− and WT mice had similar levels of RNA in all
tissues tested at 7 dpi. We recently generated an immuno-
competent model of ZIKV infection by introducing human
STAT2 into the mouse Stat2 locus (hSTAT2 KI), which allows
ZIKV to antagonize innate immune responses in mice. To con-
ﬁrm the hormone dependent effects on IFN-λ activity, we com-

































































































































































































































Fig. 2 Estradiol protects Ifnar1−/− mice from intravaginal ZIKV infection. Six-week-old Ifnar1−/− OVX mice were given a hormone replacement regimen of
estradiol, progesterone, or vehicle. Subsequently, mice were inoculated via intravaginal route with 106 FFU of ZIKV (Dakar 41525). At 6 dpi, ZIKV RNA was
measured from the vagina (a), cervix (b), uterus (c), serum (d), brain (e), and spleen (f). Dotted lines indicate the limit of detection (LOD) for each assay.
Results are pooled from two or three experiments. Bars indicate median values (Kruskal–Wallis test: *, P < 0.05 **, P < 0.01 ***, P < 0.001). Vaginal tissue
was stained using H&E or by ISH for ZIKV RNA (g). Low magniﬁcation scale bar= 500 μm, high magniﬁcation scale bar= 50 μm. Numbers of mice:
vehicle n= 7, progesterone n= 6, estradiol n= 6. Representative images are shown
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and hSTAT2 KI Ifnlr1−/− mice. We observed statistically sig-
niﬁcant increases in ZIKV infection in the vagina and uterus and
a trend toward greater infection in the cervix at 7 dpi of pro-
gesterone only-treated OVX hSTAT2 KI Ifnlr1−/− compared to
hSTAT2 KI mice (Fig. 3e–g). The increased ZIKV infection in
vagina of hSTAT2 KI Ifnlr1−/− mice was localized to the epi-
thelial layer (Fig. 4b, bottom right).
In contrast to that observed in the diestrous phase after
progesterone treatment, we did not detect differences in ZIKV
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Fig. 3 Hormone treatment modulates the severity of ZIKV infection in the vagina of OVX Ifnlr1−/− and hSTAT2 KI Ifnlr1−/−mice. Six-week-old WT, Ifnlr1−/−,
hSTAT2 KI, or hSTAT2 KI Ifnlr1−/− OVX mice were given a hormone replacement regimen of estradiol, progesterone, estradiol and progesterone, or
vehicle. WT and Ifnlr1−/− mice were treated with 1 mg of anti-Ifnar1 mAb at day −1. On day 0, mice were inoculated via intravaginal route with 106 FFU of
ZIKV (Dakar 41525). At 3 dpi, vaginal lavage was performed (b). At 7 dpi, ZIKV RNA was measured from the vagina (a, e), cervix (c, f), and uterus (d, g).
Dotted lines indicate the LOD. Results are pooled from two or three experiments. Bars indicate median values (Mann–Whitney test: (*, P < 0.05 **, P <
0.01). Numbers of mice: Vehicle: WT+ anti-Ifnar1, n= 10; Ifnlr1−/−+ anti-Ifnar1, n= 7. Progesterone: WT+ anti-Ifnar1, n= 16; Ifnlr1−/−+ anti-Ifnar1, n=
11; hSTAT2 KI, n= 7; or hSTAT2 KI Ifnlr1−/−, n= 5. Estradiol: WT+ anti-Ifnar1, n= 10; Ifnlr1−/−+ anti-Ifnar1, n= 6. Estradiol and progesterone: WT+ anti-
Ifnar1, n= 9; Ifnlr1−/−+ anti-Ifnar1, n= 13
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estradiol and progesterone-treated (proestrous phase) OVX WT
and Ifnlr1−/− mice at 7 dpi in the absence of type I IFN signaling
(Fig. 3a–d). RNA ISH also showed relatively equivalent levels of
ZIKV infection in the vagina of WT and Ifnlr1−/− mice, without
substantive differences in inﬂammation (Fig. 4a, Supplementary
Figure 3). These data suggest a hormone stage-dependent
antiviral effect of IFN-λ in the context of ZIKV infection of the
vagina.
The disparity of ZIKV infection in Ifnlr1−/− mice after
different hormone treatments might be due to differential
expression of IFN-λ or its heterodimeric receptor Ifnlr1/Il10rβ.
To evaluate this hypothesis, we measured the levels of Ifnlr1,
Il10rb, Ifnl2, and Ifnl3 mRNA by RT-qPCR in the vagina on days
1, 4, and 7 after ZIKV infection (Fig. 5). Ifnl1 is a pseudogene and
the genomic region of Ifnl4 is missing in mice37,38 and were not
measured. Consistent with our Ifnlr1−/− mouse data, estradiol
and progesterone-treated mice had little or no Ifnl2 and Ifnl3
induced 1, 4 or 7 dpi (Fig. 5a–h). However, Ifnl3 mRNA was
detected in vehicle and progesterone only-treated animals (Fig. 5g,
h). This suggests that when estradiol is absent, the vagina induces
IFN-λ in response to ZIKV infection to reduce viral burden in the
vaginal epithelium. In contrast, in the estradiol and progesterone
proestrous stage, IFN-λ is not induced sufﬁciently to confer an
antiviral effect in the vagina. Of note, only small changes in
expression of Il10rb were observed between days 0 and 7
(Fig. 5i–l), whereas Ifnlr1 mRNA was time-dependent, with the
highest expression occurring on days 1 and 4 after infection
(Fig. 5m–p).
Although OVX WT and Ifnlr1−/− mice given both estradiol
and progesterone had equivalent ZIKV infection in FRT tissues,
we speculated that cells in the vagina might respond to exogenous
IFN-λ. To test this hypothesis, OVX WT mice treated with
estradiol and progesterone and anti-Ifnar1 mAb were given
pegylated mouse IFN-λ2 via an intravaginal route 8 h before local
inoculation with ZIKV (Fig. 6). IFN-λ-treated mice sustained
lower (1274- to 137,019-fold, P < 0.05) infection in the vaginal
lavage ﬂuid, vagina, cervix, and uterus (Fig. 6a–d), and this effect
prevented dissemination to the serum, spleen, and brain
(Fig. 6e–g). The decreased levels of ZIKV infection after pegylated
IFN-λ2 treatment was conﬁrmed by RNA ISH, with markedly less
viral RNA observed in the vagina and the muscle layer of the
uterus (Fig. 6h, Supplementary Figure 6). To further explore the
possible utility of IFN-λ for preventing sexual transmission of
ZIKV, we administered pegylated IFN-λ2 to progesterone-only
treated animals. Although we observed a signiﬁcant decrease in
viral RNA levels in vaginal lavage ﬂuid at 3 dpi (73-fold, P <
0.0001) (Fig. 6a), similar levels were present in the remainder of
the FRT and peripheral tissues at 7 dpi (Fig. 6b–g). RNA ISH on
vaginal tissues also showed equivalent levels of ZIKV RNA in the
epithelial layer (Fig. 6i). Thus, while IFN-λ signaling does not
have an endogenous antiviral function in the vagina in estradiol
and progesterone-treated mice, exogenous administration can
prevent local infection and spread of ZIKV. In contrast, in
progesterone only-treated mice, exogenous administration of
IFN-λ had less antiviral effect even though higher levels of ZIKV
RNA were observed in the vagina of anti-Ifnar1 mAb-treated

































































Fig. 4 Increased ZIKV infection in the vagina of progesterone-treated OVX Ifnlr1−/− and hSTAT2 KI Ifnlr1−/− mice. Six week-old WT, Ifnlr1−/−, hSTAT2 KI,
or hSTAT2 KI Ifnlr1−/− OVX mice were given a hormone replacement regimen of estradiol, progesterone, estradiol and progesterone, or vehicle. WT and
Ifnlr1−/− mice were treated with 1 mg of anti-Ifnar1 mAb at day −1. On day 0, mice were inoculated via intravaginal route with 106 FFU of ZIKV (Dakar
41525). At 7 dpi, ZIKV RNA was stained using ISH on vaginal tissue (WT and Ifnlr1−/−, a; hSTAT2KI and hSTAT2 KI Ifnlr1−/−, b). Images are
representative of two or three experiments. Low magniﬁcation scale bar= 500 μm, high magniﬁcation scale bar= 50 μm. Numbers of mice analyzed:
Vehicle: WT+ anti-Ifnar1, n= 10; Ifnlr1−/−+ anti-Ifnar1, n= 7. Progesterone: WT+ anti-Ifnar1, n= 16; Ifnlr1−/−+ anti-Ifnar1, n= 11; hSTAT2 KI, n= 7; or
hSTAT2 KI Ifnlr1−/−, n= 5. Estradiol: WT+ anti-Ifnar1, n= 10; Ifnlr1−/−+ anti-Ifnar1, n= 6. Estradiol and progesterone: WT+ anti-Ifnar1, n= 9; Ifnlr1−/−
+ anti-Ifnar1, n= 13
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Fig. 5 IFN-λ and its receptor expression are hormone-dependent after intravaginal ZIKV infection. Six-week-old WT OVX mice were given hormone
replacement regimens of vehicle, progesterone-only, or a combination of estradiol and progesterone. Mice were treated with 1 mg of anti-Ifnar1 mAb at day
−1. On day 0, mice were inoculated via intravaginal route with 106 FFU of ZIKV (Dakar 41525); 1, 4, or 7 days after infection, total RNA was extracted, and
mRNA expression analyzed by RT-qPCR (Ifnl2 a–d; Ifnl3 e–h; Il10rβ i–l; Ifnlr1 m–p). Uninfected animals (for comparison) were harvested at the day 7 time
point. Dotted lines indicate the LOD. Results are pooled from two or three experiments. Bars indicate median values (Kruskal–Wallis test: *, P < 0.05, ***,
P < 0.001). Numbers of mice: Uninfected vehicle n= 8; Uninfected progesterone n= 10; uninfected estradiol and progesterone n= 9; day 1, vehicle n= 5;
day 1, progesterone n= 7; day 1, estradiol and progesterone n= 8; day 4, vehicle n= 5; day 4, progesterone n= 9; day 4, estradiol and progesterone n= 9;
day 7, vehicle n= 9; day 7, progesterone n= 10; and day 7, estradiol and progesterone n= 10
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Ifnlr1−/− or hSTAT2 KI Ifnlr1−/− mice (see Fig. 3a, b, e). These
phenotypes suggest that during the diestrous phase, IFN-λ
produced in the context of infection has a saturating antiviral
effect in the vagina.
Discussion
Prior studies have established that ZIKV infects speciﬁc cell types
at the maternal–fetal interface, in the brain and eye, and in the
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human cells and mice examined the antiviral role of type I and III
IFNs on intravaginal ZIKV infection. IFN-λ and IFN-β induced
an ISG signature in primary human vaginal and cervical epithelial
cells that contributed to protection against ZIKV infection. We
conﬁrmed that the estrous phase of the reproductive cycle was
protective against intravaginal infection17,18, and using transgenic
mice established that this process was independent of type I and
III IFNs. Because IFN-λ is a cytokine that acts primarily at barrier
surfaces29, we evaluated its impact on ZIKV infection in the
vagina. Unexpectedly, the inhibitory effect of IFN-λ in the vagina
was hormone stage dependent in mice. Although estradiol and
progesterone-treated mice produced low levels of IFN-λ after
intravaginal ZIKV inoculation, intravaginal administration of
pegylated IFN-λ2 protected the FRT from ZIKV infection and
subsequent dissemination. Reciprocally, progesterone only-
treated animals induced IFN-λ3 after ZIKV infection but unex-
pectedly did not show an antiviral effect of exogenous, local
pegylated IFN-λ2 treatment.
The estrous cycle and female sex hormones can modulate the
susceptibility to sexually transmitted infections including HSV,
human papilloma virus, human immunodeﬁciency virus, Neis-
seria gonorrhoeae, and Chlamydia trachomatis21,23. In the
estradiol-high estrous phase, the vagina is more resistant to
infection although the basis for this phenotype is incompletely
understood. In comparison, in progesterone-high diestrous phase,
when the reproductive tract prepares for implantation, the epi-
thelial barrier of the vagina is more susceptible to sexually
transmitted infections21. Consistent with these concepts, we show
that OVX mice were susceptible to ZIKV through the intravaginal
route when administered progesterone with or without estradiol;
in comparison, mice given only estradiol were resistant to ZIKV
infection. Since vehicle-treated OVX mice were susceptible to
ZIKV as well, we conﬁrmed that estradiol alone had an active role
in suppressing virus infection. These data agree with a prior
report showing that mice in the diestrous, but not estrous, phase
were susceptible to intravaginal infection of ZIKV18. Although
progesterone and estradiol differentially condition the vaginal
epithelium and underlying tissue, the mechanisms for the dis-
parate susceptibility to sexually transmitted infections remain
unclear21. Although one study in mice suggested an estrous cycle-
dependent protective role of IFN-ε against infections in the
vagina26, in our model, estradiol treatment conferred protection
against intravaginal ZIKV infection in mice with acquired or
genetic deﬁciencies in type I IFN signaling, suggesting that IFN-ε
was not the dominant antiviral cytokine during the estrous phase.
Since estradiol promotes proliferation of the vaginal epithelium, a
plausible explanation for the reduced susceptibility to sexually
transmitted infections during the estrous phase is that the
thickened, keratinized barrier is inherently less permeable to
pathogens33,42,43.
A recent study suggested that sexual transmission of ZIKV may
be underappreciated and contribute more signiﬁcantly to sus-
taining the virus in human population12. Because ZIKV can
disseminate to the placenta and fetus after intravaginal
infections11,17,44,45, sexual transmission might account for greater
transmission and number of congenital infections. Thus, there is
an urgent need to develop countermeasures that protect against
this transmission route. Epithelial and mucosal surfaces can
respond to IFN-λ, and IFN-λ is induced after viral (e.g., reovirus,
rotavirus, norovirus, and inﬂuenza A virus) infection to higher
levels then type I IFN at these sites46–49. Also, IFN- λ blocks
HSV-2 replication in the vaginal mucosa, in contrast to IFN-α,
which does not50. We examined the effect of endogenous IFN-λ
signaling in the vagina because of its recently described activity
against ZIKV in the placenta30,32. When mice were treated with
progesterone-only, IFN-λ3 was induced, and Ifnlr1−/− mice had
greater levels of ZIKV RNA in the vaginal epithelium than WT
mice. However, IFN-λ2 was not induced in the vagina, which
could be due to sequence differences in the promoter region of
the genes. In HIV-infected macrophages, IFN-λ1 and IFN-λ3
induced more ISGs than IFN-λ2 and conferred better protec-
tion51. Our results ostensibly contrast with data from medrox-
yprogesterone-treated, non-OVX mice, which suggested only
limited IFN-λ signaling after ZIKV infection27. In that study,
IFN-λ signaling was upregulated in the vagina after treatment
with acitretin, a retinoic acid derivative, or prior infection with
LCMV27. The differences in IFN-λ induction and signaling
between the two studies could reﬂect the experimental design,
relative levels of progesterone administered, or disparate use of
anti-Ifnar1 mAb. Apart from this, when exogenous, pegylated
IFN-λ2 was administered via intravaginal route immediately
before ZIKV infection to mice treated with only progesterone, no
additional protection was observed. These data contrast with an
IFN-λ treatment experiment in medroxyprogesterone-treated
animals where reductions in HSV-2 titers were seen in vaginal
washes52. However, in that study, no other tissue titers (vagina,
cervix, uterus) were analyzed and no other hormonal conditions
(e.g., estrogen and progesterone) were tested. Although further
studies are warranted, we speculate that the amount of endo-
genous IFN-λ produced in the progesterone-only mice provides a
saturating antiviral signal such that no further beneﬁt is acquired
from exogenous IFN-λ treatment. Alternatively, factors in the
mucosal environment (e.g., microbiome, pH, mucus, or polarity
of Ifnlr1/IL10rβ receptors on epithelium) under progesterone-
only conditions could impact the signaling potential of exogenous
IFN-λ.
To simulate the stages in the estrous cycle when both pro-
gesterone and estradiol levels are produced, we treated OVX mice
with a combination of both hormones. We observed no differ-
ences in ZIKV infection in the FRT of Ifnlr1−/− and WT mice
treated with both estradiol and progesterone. These results are
consistent with our data showing that ZIKV infection in the
vaginas of estradiol and progesterone treated mice did not induce
IFN-λ. However, when estradiol and progesterone-treated mice
were given with pegylated IFN-λ2, most animals were completely
protected against ZIKV infection. Studies in mice and possibly
NHPs that further deﬁne the hormonal stage dependence, the
durability of effect, and local inﬂammatory responses are needed
to determine the feasibility of IFN-λ as a countermeasure against
sexual transmission of ZIKV. In support of its possible utility,
Fig. 6 Pegylated IFN-λ2 protects against intravaginal ZIKV infection in estradiol and progesterone-treated OVX WT mice. Six-week-old WT OVX mice
were given a hormone replacement regimen of progesterone or estradiol and progesterone. Mice were treated with 1 mg of anti-Ifnar1 mAb at day −1. On
day 0, mice were treated via intravaginal route with 25 μg of pegylated IFN-λ2. Eight hours later, mice were inoculated with 106 FFU of ZIKV (Dakar 41525).
At 3 dpi, a vaginal lavage was performed (a). At 7 dpi, ZIKV RNA was measured from the vagina (b), cervix (c), uterus (d), serum (e), brain (f), and spleen
(g). Dotted lines indicate the LOD. Results are pooled from two or three experiments. Bars indicate median values (Mann–Whitney test: *, P < 0.05, **, P <
0.01, ****, P < 0.0001). ISH and H&E staining were performed on tissues from the vagina (Estradiol and progesterone-treated mice, h; Progesterone-treated
mice, i). Numbers of mice: Progesterone: WT+ anti-Ifnar1 mAb, IFN-λ2, n= 9; WT+ anti-Ifnar1 mAb, n= 11. Estradiol and progesterone: WT+ anti-Ifnar1
mAb, IFN-λ2, n= 9; WT+ anti-Ifnar1 mAb, n= 10. Representative images are shown
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primary human vaginal and cervical epithelial cells responded to
IFN-λ treatment with antiviral responses that blocked ZIKV
infection. One potential advantage of IFN-λ over IFN-α/β intra-
vaginal administration is that it is less inﬂammatory in
nature29,53,54, which could enhance tolerability.
The establishment of mouse models of ZIKV infection in the
lower FRT after intravaginal inoculation may be useful for testing
therapeutic agents or vaccines. Our data in mice and primary
human cells suggest that IFN-λ is a key cytokine at the epithelial
layer of the vagina and its induction and subsequent action
depends on the hormone-dependent stage of the estrous cycle.
Countermeasures against ZIKV and likely other sexually trans-
mitted infections may need to account for differences in hor-
monal status and innate immune defense programs that occur in
non-pregnant and pregnant women.
Methods
Ethics statement. This study was carried out in accordance with the recom-
mendations in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The infection and surgery protocols were approved
by the Institutional Animal Care and Use Committee at the Washington University
School of Medicine (Assurance number A3381-01, Protocols 20150222 and
20150034). Mice were anaesthetized with a ketamine hydrochloride and xylazine
mixture or isoﬂurane when inoculations or procedures were performed to reduce
animal discomfort and suffering. Animals received sustained-released buprenor-
phine and carprofen for pain management.
Viruses. ZIKV strain Dakar 41525 (Senegal, 1984) was provided by the World
Reference Center for Emerging Viruses and Arboviruses (R. Tesh). A mouse-
adapted variant of Dakar 41525 was used and has been described55. ZIKV strain
Paraiba (Brazil, 2015) was provided by S. Whitehead (NIH, Bethesda, MD)56. All
virus stocks were propagated in mycoplasma-free Vero cells (American Tissue
Culture Collection) and titrated by focus-forming assay (FFA), as described
previously6.
Mouse studies. Six-week-old, WT C57BL/6J female mice were purchased from
Jackson Laboratories (# 000664). Ifnlr1−/−50 and Ifnar1−/− mice were backcrossed
onto a C57BL/6J background. STAT2 KI mice on a C57BL/6J background were
recently described55. hSTAT2 KI Ifnlr1−/− mice were generated by standard F2
crossing. All mice were bred in a pathogen-free facility at the Washington Uni-
versity School of Medicine.
OVX surgeries were performed on 6-week-old WT, Ifnar1−/−, Ifnlr1−/−,
hSTAT2 KI, or hSTAT2 KI Ifnlr1−/− mice. Under anesthesia, a small dorsal
midline incision was made below the sternum, and the skin was separated from the
underlying abdominal wall using a scissors. A small incision was made in the
abdominal cavity and using forceps, the ovary was removed from the peritoneal
cavity and cauterized below the oviduct. The remaining tissue was placed back into
the peritoneal cavity, and the incision area was sutured closed. The process was
repeated on the contralateral side. After a 1-week recovery period, hormone pellets
(Innovative Research of America) were implanted or soluble hormones (Sigma-
Aldrich) were suspended in sunﬂower oil and injected. Time-released pellets were
placed under the skin, releasing 10 mg of progesterone (P4) or 0.1 mg of 17β-
estradiol, or vehicle pellets (that contained no hormones) over 21 days for an
average dose of 500 μg or progesterone and/or 5 μg of estradiol per day. For
hormone injections, mice were administered oil only (vehicle), 200 μg of estradiol
and/or 2 mg of progesterone subcutaneously in the back of the animals. After
hormone treatment, mice were treated with 1 mg of anti-Ifnar1 mAb (MAR1-5A3,
produced by Leinco Technologies)57 and inoculated intravaginally with 106 FFU of
ZIKV (Dakar 41525). At 3 dpi, a vaginal lavage was performed: two 30 μL washes
with PBS were added to 30 μL of DMEM supplemented with 5% FBS and frozen at
−80 °C. Tissues from WT and Ifnlr1−/−, hSTAT2 KI, or hSTAT2 KI Ifnlr1−/−
mice were harvested at 7 dpi. Tissues from Ifnar1−/− mice were harvested at 6 dpi.
No differences in the different hormone treatments (pellets versus injections) were
observed in terms of estrous cycle or susceptibility to ZIKV infection.
IFN-λ treatment of mice. OVX WT C57BL/6 J were treated with estradiol and
progesterone or progesterone-only as described above. One week later, mice
received 1 mg of anti-Ifnar1 mAb, and the following day some animals received 25
μg of pegylated IFN-λ2 (Bristol-Myers Squibb) via intravaginal route. Eight hours
later, mice were inoculated via intravaginal route with 106 FFU of ZIKV (Dakar
41525) and processed at 3 and 7 dpi as described above.
Human vaginal and cervical epithelial cell experiments. HVECs and HCECs
from four or three deceased healthy donors, respectively (purchased from Lifeline
Cell Technology), were maintained in ReproLife Reproductive Medium (Lifeline)
according to manufacturer’s instructions. Information on the menstrual phase of
human donors was not available, as the samples were de-identiﬁed. Cells were
pretreated with human recombinant IFN-β or IFN-λ (100 ng/mL; R&D Systems)
for ~18 h in quadruplicate before harvest, total RNA was extracted using a Gen-
Elute Total RNA Miniprep Kit (Sigma). Following isolation and treatment with
DNAse (Sigma), RNA was reverse transcribed using an iScript cDNA synthesis kit
(BioRad) containing 1 μg of total RNA. ISG mRNA expression was determined by
RT-qPCR using IQ SYBR Green Supermix (BioRad) in a BioRad CFX96 touch real
time PCR detection system or an Applied Biosystems StepOnePlus real time PCR
machine as reported previously32,58. Primer sequences are GAPDH (5′-
GAAGGTCGGAGTCAACGGATTT-3′ and 5′-GAATTTGCCATGGGTGGAAT-
3′), IFI44L (5′-TGCAGAGAGGATGAGAATATC-3′ and 5′- ACTAAAGTGG
ATGATTGCAG-3′), OAS1 (5′-ATAAAAGCAAACAGGTCTGG-3′ and 5′-
TCTGGCAAGAGATAGTCTTC-3′), OASL (5′-GTACCAGCAGTATGTGAAAG-
3′ and 5′-ATGGTTAGAAGTTCAAGAGC-3′), and MX1 (5′-F: CTGACTCTAA
TAGACCTTCCTG-3′ and R: 5′-GATCTTATACCCAATGTCAGC-3′). Cells were
inoculated with ZIKV (Paraiba, MOI of 3) for 48 h after pretreatment with med-
ium, IFN-β or IFN-λ. Viral burden was determined from supernatants using an
FFA as previously described31.
Virus titration. Tissues were homogenized in 300–600 μL of DMEM supple-
mented with 10% FBS using stainless-steel beads in a Bullet Blender Storm 24
homogenizer instrument (Next Advance) for 1–2 min. Homogenates were clariﬁed
by centrifugation at 6000×g for 5 min and stored at −80 °C. RNA was extracted
using an Applied Biosystems 5x MagMax RNA 96 viral isolation kit (Thermo
Scientiﬁc) and a Kingﬁsher duo prime extraction machine (Thermo Scientiﬁc).
ZIKV RNA levels were determined by one-step quantitative RT–qPCR using an
Applied Biosystems Taqman RNA-to-Ct 1-step kit (Thermo Scientiﬁc) on an ABI
7500 Fast Instrument using standard cycling conditions. Published primer/probe
sets for RT-qPCR of ZIKV were used1.
1183F: 5′-CCACCAATGTTCTCTTGCAGACATATTG-3′;
1268R: 5′-TTCGGACAGCCGTTGTCCAACACAAG-3′;
and probes (1213F): 5′-56-FAM/AGCCTACCT/ZEN/TGACAAGCAGTC/
3IABkFQ-3′.
Viral burden was expressed on a log10 scale as ZIKV RNA equivalents per gram
or milliliter after comparison with a standard curve produced using serial tenfold
dilutions of ZIKV RNA1.
Histology and RNA ISH. Tissues were collected and ﬁxed overnight in 4% par-
aformaldehyde (PFA) in PBS. Vaginal and uterine tissues from uninfected and
infected mice were cut into 3-μm-thick sections followed by hematoxylin and eosin
(H&E) staining. RNA ISH was performed using RNAscope 2.5 (Advanced Cell
Diagnostics) according to the manufacturer’s instructions. PFA-ﬁxed parafﬁn-
embedded tissue sections were deparafﬁnized by incubating for 60 min at 60 °C.
Endogenous peroxidases were quenched with H2O2 for 10 min at room tempera-
ture. Slides were boiled for 15 min in RNAscope Target Retrieval Reagents and
incubated for 30 min in RNAscope Protease and before probe hybridization. The
probe targeting ZIKV RNA was designed and synthesized by Advanced Cell
Diagnostics (Catalog #467871). Positive (targeting plr2a gene) and negative (tar-
geting bacterial gene dapB) control probes also were obtained from Advanced Cell
Diagnostics (Catalog #312471 and #310043, respectively) and used for all tissue
staining. Slides were counterstained with Gill’s hematoxylin and visualized using
bright-ﬁeld microscopy.
IFN-λ RT-qPCR in mouse vaginal tissue. Vaginal tissues were harvested at 1, 4,
and 7 dpi from hormone or vehicle-treated OVX mice and homogenized as
described above. Total RNA was extracted using a Quick-RNA Microprep Kit
(Zymo Research Catalog #11-327M) and DNAse treatment was performed. Ifnlr1,
Il10rβ, Ifnl2, and Ifnl3 were quantiﬁed by RT-qPCR as described above and nor-
malized to Gapdh expression. The following PrimeTime primers (IDT) were used:
Ifnlr1: Mm.PT.58.10781457, Il10rβ: Mm.PT.58.29421186, Ifnl2: Mm.
PT.58.31485549, and Ifnl3: Mm.PT.58.8956530, and Gapdh: Mm.PT.39a.1.
RNAseq on IFN-treated HVECs. Total RNA was extracted as described above,
and RNASeq was performed as described31,32,58. Brieﬂy, libraries were prepared
with the Ultra Library Preparation kit (New England BioLabs), and quality was
determined using the Qubit assay (Thermo Scientiﬁc) and Agilent 2100 Bioana-
lyzer. Sequencing was performed with the Illumina HiSeq2500 rapid-run mode,
and CLC Genomics Workbench 9.0 (Qiagen) was used to map sequence data to the
human reference genome (hg19). Differentially expressed genes were identiﬁed
using the DESeq2 package in R59 with a signiﬁcance cut-off described in the Figure
legends. Heatmaps were generated using MeV software and were based upon log
(RPKM) values. Gene set enrichment analysis (GSEA) v2.060 was used for
enrichment analyses, with false discovery rates (FDRs) described in the ﬁgure
legends. Files associated with RNASeq from the current study have been deposited
into Sequence Read Archive Files (SRA).
RNAseq on OVX hormone-treated WT mice. OVX and hormone treatment was
performed on WT mice as described above. Total RNA was extracted from vaginal
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tissue 7 days after hormone treatment began as described above. Samples were
processed for RNA-seq analysis at the Genome Techonology Access Center at
Washington University. Fragments were sequenced on an Illumina HiSeq-2500
using single reads extending 50 bases. Brieﬂy, RNA-seq reads were aligned to the
Ensembl 76 top-level assembly with STAR (version 2.0.4b). Gene counts were
derived from the number of uniquely aligned unambiguous reads by Subread:
featureCount (version 1.4.5). Transcript counts were produced by Sailﬁsh (version
0.6.3). Sequencing performance was assessed for total number of aligned reads,
total number of uniquely aligned reads, genes and transcripts detected, ribosomal
fraction, junction saturation, and read distribution over known gene models with
RSeQC (version 2.3). All gene-level counts were imported into the R/Bioconductor
package Deseq2 and normalized values (rlog normalization) were used for heatmap
generation using the Phantasus* web-service (https://artyomovlab.wustl.edu/
phantasus/).
Statistical analysis. Unless otherwise speciﬁed, all data were analyzed with
GraphPad Prism and DeSeq2 package in R software. Statistical signiﬁcance of Gene
Set Enrichment Analysis (GSEA) was based on the family wise-error rate. For viral
burden analysis, the log10 transformed titers were analyzed by Mann–Whitney,
one-way ANOVA, or a Kruskal–Wallis test with multiple comparison correction. A
P value of <0.05 indicated statistically signiﬁcant differences.
Reporting Summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All data generated or analyzed during this study are included in this published
article and its supplementary information ﬁles or have been placed in public
repositories (RNAseq data, described above). RNAseq data on OVX hormone-
treated WT mice have been deposited in GEO (GSE122591). RNAseq on IFN-
treated human vaginal epithelial cells data number is deposited in Sequence Read
Archives (PRJNA506090). All data and materials are available upon request.
Received: 4 September 2018 Accepted: 30 November 2018
References
1. Govero, J. et al. Zika virus infection damages the testes in mice. Nature 540,
438–442 (2016).
2. Joguet, G. et al. Effect of acute Zika virus infection on sperm and virus
clearance in body ﬂuids: a prospective observational study. Lancet Infect. Dis.
17, 1200–1208 (2017).
3. Lazear, H. M. & Diamond, M. S. Zika virus: new clinical syndromes and its
emergence in the Western Hemisphere. J. Virol. 90, 4864–4875 (2016).
4. Adams Waldorf, K. M. et al. Fetal brain lesions after subcutaneous inoculation
of Zika virus in a pregnant nonhuman primate. Nat. Med. 22, 1256–1259
(2016).
5. Carvalho, F. H. et al. Associated ultrasonographic ﬁndings in fetuses with
microcephaly because of suspected Zika virus (ZIKV) infection during
pregnancy. Prenat. Diagn. 36, 882–887 (2016).
6. Lazear, H. M. et al. A mouse model of Zika virus pathogenesis. Cell Host
Microbe 19, 720–730 (2016).
7. Mlakar, J. et al. Zika virus associated with microcephaly. N. Engl. J. Med. 374,
951–958 (2016).
8. Duggal, N. K. et al. Frequent zika virus sexual transmission and prolonged
viral RNA shedding in an immunodeﬁcient mouse model. Cell Rep. 18,
1751–1760 (2017).
9. Magalhaes, T., Foy, B. D., Marques, E. T. A., Ebel, G. D. & Weger-Lucarelli, J.
Mosquito-borne and sexual transmission of Zika virus: recent developments
and future directions. Virus Res. 254, 1–9 (2018).
10. D’Ortenzio, E. et al. Evidence of sexual transmission of Zika virus. N. Engl. J.
Med. 374, 2195–2198 (2016).
11. Russell, K. et al. Male-to-female sexual transmission of Zika virus-United
States, January-April 2016. Clin. Infect. Dis. 64, 211–213 (2017).
12. Allard, A., Althouse, B. M., Hebert-Dufresne, L. & Scarpino, S. V. The risk of
sustained sexual transmission of Zika is underestimated. PLoS Pathog. 13,
e1006633 (2017).
13. Mead, P. S. et al. Zika virus shedding in semen of symptomatic infected men.
N. Engl. J. Med. 378, 1377–1385 (2018).
14. Ma, W. et al. Zika virus causes testis damage and leads to male infertility in
mice. Cell 167, 1511–1524 e1510 (2016).
15. Uraki, R. et al. Zika virus causes testicular atrophy. Sci. Adv. 3, e1602899
(2017).
16. Mansuy, J. M. et al. Zika virus in semen and spermatozoa. Lancet Infect. Dis.
16, 1106–1107 (2016).
17. Yockey, L. J. et al. Vaginal exposure to Zika virus during pregnancy leads to
fetal brain infection. Cell 166, 1247–1256.e4 (2016).
18. Tang, W. W. et al. A mouse model of Zika virus sexual transmission and
vaginal viral replication. Cell Rep. 17, 3091–3098 (2016).
19. Hirsch, A. J. et al. Zika Virus infection of rhesus macaques leads to viral
persistence in multiple tissues. PLoS Pathog. 13, e1006219 (2017).
20. Carroll, T. et al. Zika virus preferentially replicates in the female reproductive
tract after vaginal inoculation of rhesus macaques. PLoS Pathog. 13, e1006537
(2017).
21. Wira, C. R., Rodriguez-Garcia, M. & Patel, M. V. The role of sex hormones in
immune protection of the female reproductive tract. Nat. Rev. Immunol. 15,
217–230 (2015).
22. Schaefer, K., Brown, N., Kaye, P. M. & Lacey, C. J. Cervico-vaginal
immunoglobulin G levels increase post-ovulation independently of
neutrophils. PLoS ONE 9, e114824 (2014).
23. Teepe, A. G., Allen, L. B., Wordinger, R. J. & Harris, E. F. Effect of the estrous
cycle on susceptibility of female mice to intravaginal inoculation of herpes
simplex virus type 2 (HSV-2). Antiviral Res. 14, 227–235 (1990).
24. Smith, S. M., Baskin, G. B. & Marx, P. A. Estrogen protects against vaginal
transmission of simian immunodeﬁciency virus. J. Infect. Dis. 182, 708–715
(2000).
25. Stifter, S. A. et al. Deﬁning the distinct, intrinsic properties of the novel type I
interferon, epsilon. J. Biol. Chem., https://doi.org/10.1074/jbc.M117.800755
(2017).
26. Fung, K. Y. et al. Interferon-epsilon protects the female reproductive tract
from viral and bacterial infection. Science 339, 1088–1092 (2013).
27. Khan, S. et al. Dampened antiviral immunity to intravaginal exposure to RNA
viral pathogens allows enhanced viral replication. J. Exp. Med. 213, 2913–2929
(2016).
28. Katz, H. I., Waalen, J. & Leach, E. E. Acitretin in psoriasis: an overview of
adverse effects. J. Am. Acad. Dermatol. 41, S7–S12 (1999).
29. Lazear, H. M., Nice, T. J. & Diamond, M. S. Interferon-lambda: immune
functions at barrier surfaces and beyond. Immunity 43, 15–28 (2015).
30. Jagger, B. W. et al. Gestational stage and IFN-lambda signaling regulate ZIKV
infection in utero. Cell Host Microbe 22, 366–376.e3 (2017).
31. Corry, J., Arora, N., Good, C. A., Sadovsky, Y. & Coyne, C. B. Organotypic
models of type III interferon-mediated protection from Zika virus infections
at the maternal-fetal interface. Proc. Natl Acad. Sci. USA 114, 9433–9438
(2017).
32. Bayer, A. et al. Type III interferons produced by human placental trophoblasts
confer protection against Zika virus infection. Cell Host Microbe 19, 705–712
(2016).
33. Gillgrass, A. E., Fernandez, S. A., Rosenthal, K. L. & Kaushic, C. Estradiol
regulates susceptibility following primary exposure to genital herpes simplex
virus type 2, while progesterone induces inﬂammation. J. Virol. 79, 3107–3116
(2005).
34. Rossi, S. L. et al. Characterization of a novel murine model to study Zika virus.
Am. J. Trop. Med. Hyg. 94, 1362–1369 (2016).
35. Kumar, A. et al. Zika virus inhibits type-I interferon production and
downstream signaling. EMBO Rep. 17, 1766–1775 (2016).
36. Grant, A. et al. Zika virus targets human STAT2 to inhibit type I interferon
signaling. Cell Host Microbe 19, 882–890 (2016).
37. Hemann, E. A., Gale, M. Jr. & Savan, R. Interferon lambda genetics and
biology in regulation of viral control. Front. Immunol. 8, 1707 (2017).
38. Lasfar, A. et al. Characterization of the mouse IFN-lambda ligand-receptor
system: IFN-lambdas exhibit antitumor activity against B16 melanoma.
Cancer Res. 66, 4468–4477 (2006).
39. Rosenberg, A. Z., Yu, W., Hill, D. A., Reyes, C. A. & Schwartz, D. A. Placental
pathology of Zika virus: viral infection of the placenta induces villous stromal
macrophage (Hofbauer Cell) proliferation and hyperplasia. Arch. Pathol. Lab.
Med. 141, 43–48 (2017).
40. Schwartz, D. A. Viral infection, proliferation, and hyperplasia of Hofbauer
cells and absence of inﬂammation characterize the placental pathology of
fetuses with congenital Zika virus infection. Arch. Gynecol. Obstet. 295,
1361–1368 (2017).
41. de Paula Freitas, B., Ventura, C. V., Maia, M. & Belfort, R. Jr. Zika virus and
the eye. Curr. Opin. Ophthalmol. 28, 595–599 (2017).
42. Patton, D. L. et al. Epithelial cell layer thickness and immune cell populations
in the normal human vagina at different stages of the menstrual cycle. Am. J.
Obstet. Gynecol. 183, 967–973 (2000).
43. Kaushic, C., Zhou, F., Murdin, A. D. & Wira, C. R. Effects of estradiol and
progesterone on susceptibility and early immune responses to Chlamydia
trachomatis infection in the female reproductive tract. Infect. Immun. 68,
4207–4216 (2000).
44. Deckard, D. T. et al. Male-to-male sexual transmission of Zika virus-Texas,
January 2016. MMWR Morb. Mortal. Wkly Rep. 65, 372–374 (2016).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-07993-2 ARTICLE
NATURE COMMUNICATIONS |          (2019) 10:280 | https://doi.org/10.1038/s41467-018-07993-2 | www.nature.com/naturecommunications 11
45. Davidson, A., Slavinski, S., Komoto, K., Rakeman, J. & Weiss, D. Suspected
female-to-male sexual transmission of Zika virus - New York City, 2016.
MMWR Morb. Mortal. Wkly. Rep. 65, 716–717 (2016).
46. Sommereyns, C., Paul, S., Staeheli, P. & Michiels, T. IFN-lambda (IFN-
lambda) is expressed in a tissue-dependent fashion and primarily acts on
epithelial cells in vivo. PLoS Pathog. 4, e1000017 (2008).
47. Baldridge, M. T. et al. Expression of Ifnlr1 on intestinal epithelial cells is
critical to the antiviral effects of interferon lambda against norovirus and
reovirus. J. Virol. 91, https://doi.org/10.1128/JVI.02079-16 (2017).
48. Pott, J. et al. IFN-lambda determines the intestinal epithelial antiviral host
defense. Proc. Natl Acad. Sci. USA 108, 7944–7949 (2011).
49. Jewell, N. A. et al. Lambda interferon is the predominant interferon induced
by inﬂuenza A virus infection in vivo. J. Virol. 84, 11515–11522 (2010).
50. Ank, N. et al. An important role for type III interferon (IFN-lambda/IL-28) in
TLR-induced antiviral activity. J. Immunol. 180, 2474–2485 (2008).
51. Wang, Y. et al. Comparison of antiviral activity of lambda-interferons against
HIV replication in macrophages. J. Interferon Cytokine Res 35, 213–221 (2015).
52. Ank, N. et al. Lambda interferon (IFN-lambda), a type III IFN, is induced by
viruses and IFNs and displays potent antiviral activity against select virus
infections in vivo. J. Virol. 80, 4501–4509 (2006).
53. Banos-Lara Mdel, R. et al. Impact and regulation of lambda interferon
response in human metapneumovirus infection. J. Virol. 89, 730–742 (2015).
54. Jordan, W. J. et al. Human interferon lambda-1 (IFN-lambda1/IL-29)
modulates the Th1/Th2 response. Genes Immun. 8, 254–261 (2007).
55. Gorman, M. J. et al. An immunocompetent mouse model of Zika virus
infection. Cell Host Microbe 23, 672–685.e6 (2018).
56. Tsetsarkin, K. A. et al. A full-length infectious cDNA clone of Zika virus from
the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host
Interactions and Vaccine Development. mBio 7, https://doi.org/10.1128/
mBio.01114-16 (2016).
57. Sheehan, K. C. et al. Blocking monoclonal antibodies speciﬁc for mouse IFN-
alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo
hydrodynamic transfection. J. Interferon Cytokine Res. 26, 804–819 (2006).
58. McConkey, C. A. et al. A three-dimensional culture system recapitulates
placental syncytiotrophoblast development and microbial resistance. Sci. Adv.
2, e1501462 (2016).
59. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and
dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
60. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based
approach for interpreting genome-wide expression proﬁles. Proc. Natl Acad.
Sci. USA 102, 15545–15550 (2005).
Acknowledgements
This work was supported by grants from the NIH (R01 AI073755, R01 AI127828,
and R01 HD091218 to M.S.D; T32AI055397 to E.C.; R01 AI081759 and HD075665 to
C.B.C.; and R01 HD083895 to K.H.M.). In addition, work was supported by a
Burroughs Wellcome Investigators in the Pathogenesis of Infectious Disease
Award (C.B.C) and the Children’s Hospital of Pittsburgh of the UPMC Health System
(C.B.C. and N.A.) K.Z. was supported by the Government of the Russian Federation
(Grant 08-08). We thank Haina Shin for experimental advice and Sean Doyle
(Zymogenetics, a Bristol-Myers Squibb company) for providing the Ifnlr1−/− mice
and pegylated IFN-λ2.
Author contributions
E.A.C., S.M.S., N.A., K.Z., M.N.A., C.B.C., K.H.M. and M.S.D. designed the experiments.
E.A.C., S.M.S. and N.A. performed the experiments. E.A.C., S.M.S., N.A., K.Z., M.N.A.
and C.B.C. performed data analysis. E.A.C. and M.S.D. wrote the initial draft of the
manuscript with other authors providing editorial comments.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
018-07993-2.
Competing interests: M.S.D. is a consultant for Inbios and Sanoﬁ-Pasteur and is on the
Scientiﬁc Advisory Board of Moderna. The remaining authors declare no competing
interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Journal peer review information: Nature Communications thanks the anonymous
reviewers for their contribution to the peer review of this work.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-07993-2
12 NATURE COMMUNICATIONS |          (2019) 10:280 | https://doi.org/10.1038/s41467-018-07993-2 | www.nature.com/naturecommunications
